Oncotarget’s reputation as a prominent online research platform remains unsurpassed. As a testament to their proficiency, the research site has categorically listed journals in chronological order based on the title, type, total documents, total cites, citable documents, and the reference documents. More importantly, each journal is sequentially listed based on their index ranking as a means of differentiating the priority levels. In essence, searching for a document is no longer an insurmountable task especially with the provision of carefully crafted guidelines in each section. For instance, a cancer journal for clinicians possesses a 131 index ranking while the nature reviews cancer possesses a 355 index ranking. IntegraGen recently grabbed the headlines by publishing an edifying article in Oncotarget.The company has become synonymous with transforming biological samples into genomic information and utilizing such diagnostic tools to determine the extent of tumor infection with the available samples.
Titled “Association between miR-31-3p expression and cetuximab efficacy in invalids with wild-type metastatic colorectal cancer,” the article confirms the underlying relationship between efficacy of anti-EGFR treatment and miR-31-3p expression. In a much broader analysis, the journal ratifies that a comprehensive analysis of miR-31-3p levels in invalids suffering from metastatic colorectal cancer can be adopted as a complementary diagnostic tool to assist patients aimed at benefitting from anti-EGFR therapy. According to Prof. John Bridgewater, a leading medical oncologist stationed at University College London Cancer Institute, the medical team is beyond elated to continue publishing clinical data which provides practitioners with comprehensive details regarding therapeutic tailoring approaches to better understanding colorectal cancer.The publication assures that the overwhelming evidence on the merits of measuring miR-31-3P in cancerous tissues should be sufficient in diagnosing and treating metastatic colorectal cancer.
To meet high demands, Oncotarget has embarked on a wise business move to publish two journals weekly per section. Widely known as a leading multidisciplinary journal focusing on a diverse range of topics, the strategic move is undoubtedly geared at not only attracting more readers but also retaining the existing ones. In essence, the site works closely with practitioners, medical field researchers, and the general public.